FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594056444> ?p ?o ?g. }

• W2594056444 endingPage "481" @default.
• W2594056444 startingPage "473" @default.
• W2594056444 abstract "Purpose To investigate whether oral, long-chain omega-3 (ω-3) essential fatty acid (EFA) supplementation, for 3 months, induces changes to the central corneal sub-basal nerve plexus in dry eye disease and whether nerve alterations correlate with clinical findings. Methods This prospective, comparative study involved the final 12 participants enrolled in a randomised, double-masked, placebo-controlled clinical trial of 60 participants with moderate dry eye disease. Participants received either placebo (olive oil 1500 mg/day; n = 4) or ω-3 EFA supplements (~1000 mg/day eicosapentaenoic acid + ~500 mg/day docosahexaenoic acid; n = 8) for 90 days. The main outcome measure was the mean change in central corneal sub-basal plexus nerve parameters between days one and 90, quantified using in vivo confocal microscopy. Secondary outcomes included mean change in tear osmolarity, corneal dendritic cell density and basal epithelial cell density. Results Compared with baseline, the reduction in OSDI score and tear osmolarity at day 90 were greater in the ω-3 EFA group than the placebo group (OSDI: ω-3 EFA, mean ± SEM: −15.6 ± 2.8 vs placebo: −2.8 ± 4.1 units, t5 = 2.6, p = 0.04; tearosmolarity: ω-3 EFA: −22.63 ± 5.7 vs placebo: −8 ± 2.7 mOsmol/L, t9 = 2.3, p = 0.04). At day 90, corneal total nerve branch density (CTBD: 91.1 ± 8.6 vs 45.1 ± 13.4 branches/mm2, F1,10 = 14, p = 0.004) and corneal nerve branch density on the main fibre (CNBD: 63.4 ± 6.5 vs 27.9 ± 11.5 branches/mm2, F1,10 = 6, p = 0.03) were higher in the ω-3 EFA group compared with placebo. Relative to day 1, CNBD (branches/mm2) increased at day 90 in the ω-3 EFA group (+20.0 ± 9.2, t8 = 3.2 p = 0.01) compared with placebo (−10.8 ± 3.2). Similar changes were evident for corneal nerve fibre length (CNFL, mm/mm2), which increased from baseline at day 90 in the omega-3 EFA group (+2.9 ± 1.6, t8 = 3.4 p = 0.01) compared with placebo (−2.7 ± 0.5). There was a negative correlation between CTBD and tear osmolarity (r10 = −0.70, p = 0.01). No significant changes were observed for basal epithelial cell or corneal dendritic cell density. Conclusion These pilot study findings suggest that ω-3 EFA supplementation imparts neuroprotective effects in the corneal sub-basal plexus that correlate with the extent of tear osmolarity normalisation." @default.
• W2594056444 created "2017-03-16" @default.
• W2594056444 creator A5027270996 @default.
• W2594056444 creator A5071899611 @default.
• W2594056444 creator A5058120098 @default.
• W2594056444 date "2017-03-12" @default.
• W2594056444 modified "2023-09-26" @default.
• W2594056444 title "Omega‐3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study" @default.
• W2594056444 cites W1739691545 @default.
• W2594056444 cites W1965457110 @default.
• W2594056444 cites W1968528693 @default.
• W2594056444 cites W1977804463 @default.
• W2594056444 cites W1982402889 @default.
• W2594056444 cites W1983711728 @default.
• W2594056444 cites W1992307218 @default.
• W2594056444 cites W1995822290 @default.
• W2594056444 cites W2001202192 @default.
• W2594056444 cites W2013281526 @default.
• W2594056444 cites W2024642440 @default.
• W2594056444 cites W2034210776 @default.
• W2594056444 cites W2056565496 @default.
• W2594056444 cites W2060683634 @default.
• W2594056444 cites W2061200379 @default.
• W2594056444 cites W2065645867 @default.
• W2594056444 cites W2070610048 @default.
• W2594056444 cites W2075258965 @default.
• W2594056444 cites W2086970953 @default.
• W2594056444 cites W2088866662 @default.
• W2594056444 cites W2095701392 @default.
• W2594056444 cites W2102005177 @default.
• W2594056444 cites W2126039574 @default.
• W2594056444 cites W2135410431 @default.
• W2594056444 cites W2136182528 @default.
• W2594056444 cites W2143726221 @default.
• W2594056444 cites W2147926338 @default.
• W2594056444 cites W2154266087 @default.
• W2594056444 cites W2156165690 @default.
• W2594056444 cites W2158113786 @default.
• W2594056444 cites W2259910621 @default.
• W2594056444 cites W2316811969 @default.
• W2594056444 cites W2327916450 @default.
• W2594056444 cites W2345878622 @default.
• W2594056444 cites W2417115835 @default.
• W2594056444 cites W2475237810 @default.
• W2594056444 cites W2493099616 @default.
• W2594056444 cites W2521601013 @default.
• W2594056444 cites W2547255159 @default.
• W2594056444 cites W2560343879 @default.
• W2594056444 cites W2596391620 @default.
• W2594056444 cites W2597267452 @default.
• W2594056444 doi "https://doi.org/10.1111/opo.12365" @default.
• W2594056444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28295445" @default.
• W2594056444 hasPublicationYear "2017" @default.
• W2594056444 type Work @default.
• W2594056444 sameAs 2594056444 @default.
• W2594056444 citedByCount "50" @default.
• W2594056444 countsByYear W25940564442017 @default.
• W2594056444 countsByYear W25940564442018 @default.
• W2594056444 countsByYear W25940564442019 @default.
• W2594056444 countsByYear W25940564442020 @default.
• W2594056444 countsByYear W25940564442021 @default.
• W2594056444 countsByYear W25940564442022 @default.
• W2594056444 countsByYear W25940564442023 @default.
• W2594056444 crossrefType "journal-article" @default.
• W2594056444 hasAuthorship W2594056444A5027270996 @default.
• W2594056444 hasAuthorship W2594056444A5058120098 @default.
• W2594056444 hasAuthorship W2594056444A5071899611 @default.
• W2594056444 hasBestOaLocation W25940564442 @default.
• W2594056444 hasConcept C118487528 @default.
• W2594056444 hasConcept C126322002 @default.
• W2594056444 hasConcept C142724271 @default.
• W2594056444 hasConcept C185592680 @default.
• W2594056444 hasConcept C19038510 @default.
• W2594056444 hasConcept C204787440 @default.
• W2594056444 hasConcept C27081682 @default.
• W2594056444 hasConcept C2777171753 @default.
• W2594056444 hasConcept C2777723521 @default.
• W2594056444 hasConcept C543025807 @default.
• W2594056444 hasConcept C55493867 @default.
• W2594056444 hasConcept C71924100 @default.
• W2594056444 hasConcept C90924648 @default.
• W2594056444 hasConceptScore W2594056444C118487528 @default.
• W2594056444 hasConceptScore W2594056444C126322002 @default.
• W2594056444 hasConceptScore W2594056444C142724271 @default.
• W2594056444 hasConceptScore W2594056444C185592680 @default.
• W2594056444 hasConceptScore W2594056444C19038510 @default.
• W2594056444 hasConceptScore W2594056444C204787440 @default.
• W2594056444 hasConceptScore W2594056444C27081682 @default.
• W2594056444 hasConceptScore W2594056444C2777171753 @default.
• W2594056444 hasConceptScore W2594056444C2777723521 @default.
• W2594056444 hasConceptScore W2594056444C543025807 @default.
• W2594056444 hasConceptScore W2594056444C55493867 @default.
• W2594056444 hasConceptScore W2594056444C71924100 @default.
• W2594056444 hasConceptScore W2594056444C90924648 @default.
• W2594056444 hasFunder F4320320471 @default.
• W2594056444 hasFunder F4320334705 @default.
• W2594056444 hasIssue "4" @default.
• W2594056444 hasLocation W25940564441 @default.

• next